News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Boehringer Ingelheim Corporation Release: New Linagliptin Phase III Data Demonstrate Significant Reductions in Blood Glucose With No Additional Risk of Hypoglycaemia When Combined With Insulin in Patients With Type 2 Diabetes


6/11/2012 10:59:39 AM

INGELHEIM, Germany & INDIANAPOLIS--(BUSINESS WIRE)--Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) presented results from a randomised Phase III clinical trial and a post-hoc analysis for linagliptin at ADA. The results showed that adults with type 2 diabetes (T2D) treated with linagliptin in combination with certain other diabetes therapies achieved clinically meaningful blood glucose control.1,2 Linagliptin is a once-daily tablet that is used along with diet and exercise to improve glycaemic control in adults with T2D.3,4

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES